MCID: IRS003
MIFTS: 31

Iris Disease malady

Categories: Eye diseases

Aliases & Classifications for Iris Disease

Aliases & Descriptions for Iris Disease:

Name: Iris Disease 12 14
Iris Diseases 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:240
MeSH 42 D007499
NCIt 47 C34737
UMLS 69 C0022078

Summaries for Iris Disease

MalaCards based summary : Iris Disease, also known as iris diseases, is related to dystonia-1, torsion and acquired hyperkeratosis. An important gene associated with Iris Disease is PAX6 (Paired Box 6), and among its related pathways/superpathways is Mesodermal Commitment Pathway. The drugs Cyclopentolate and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are digestive/alimentary and muscle

Related Diseases for Iris Disease

Diseases related to Iris Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
id Related Disease Score Top Affiliating Genes
1 dystonia-1, torsion 10.3 PAX6 WT1
2 acquired hyperkeratosis 10.3 OPTN PHEX
3 mixed gonadal dysgenesis 10.3 OPTN PHEX
4 multiple cranial nerve palsy 10.3 OPTN PEX19
5 bladder calculus 10.2 MRAP PAX6
6 joubert syndrome 6 10.2 OPTN PAX6
7 visceral leishmaniasis 10.2 MRAP WT1
8 acute maxillary sinusitis 10.2 MRAP PHEX
9 mechanical strabismus 10.2 OPTN PEX19 PHEX
10 morbid obesity and spermatogenic failure 10.2 LOXL1 OPTN PHEX
11 colorectal cancer 5 10.2 LOXL1 OPTN PHEX
12 vibratory urticaria 10.2 MRAP PEX19
13 lacrimal duct obstruction 10.2 IGF2 PAX6
14 disease_ontology 10.2 FSHB PAX6 WT1
15 cicatricial ectropion 10.2 HDAC9 OPTN
16 scurvy 10.1 LOXL1 PITX2
17 coloboma of optic nerve 10.1 ELP4 PAX6
18 conjugate gaze palsy 10.1 MRAP OPTN
19 hemorrhagic fever 10.1 IGF2 WT1
20 intermixed schwannian stroma-rich ganglioneuroblastoma 10.1 IGF2 PAX6 WT1
21 tubulointerstitial nephritis with uveitis 10.1 HDAC9 MRAP
22 olecranon bursitis 10.1 LOXL1 OPTN PEX19 PHEX
23 kcnj10-related pendred syndrome 10.1 FOXC1 PAX6
24 meier-gorlin syndrome 1 10.1 HDAC9 OPTN PAX6
25 prostate disease 10.1 MRAP OPTN
26 thyroid dyshormonogenesis 3 10.0 FOXC1 OPTN
27 pseudopterygium 10.0 LOXL1 OPTN PAX6 PEX19 PHEX
28 ring dermoid of cornea 10.0 PAX6 PITX2
29 peters anomaly 10.0 FOXC1 OPTN PAX6
30 cerebral cavernous malformations-2 10.0 IGF2 PAX6 WT1
31 diffuse glomerulonephritis 9.9 IGF2 WT1
32 cardiac arrhythmia, ankyrin-b-related 9.9 FOXC1 PITX2
33 chronic tympanitis 9.9 FOXC1 HDAC9 OPTN
34 orbital granuloma 9.9 FOXC1 PAX6 PITX2
35 aphakia, congenital primary 9.9 FOXC1 PAX6 PITX2
36 cornea plana 9.8 FOXC1 PAX6 PITX2
37 scapuloperoneal syndrome, myopathic type 9.8 FOXC1 OPTN PITX2
38 conjunctival folliculosis 9.8 FOXC1 OPTN PITX2
39 deafness, autosomal recessive 91 9.7 FOXC1 OPTN PAX6 PITX2
40 jph2-related familial hypertrophic cardiomyopathy 9.7 ELP4 FOXC1 PAX6 PITX2
41 muir-torre syndrome 9.7 FOXC1 HDAC9 PAX6 PITX2
42 hypertrophy of breast 9.6 FOXC1 OPTN PAX6 PHEX PITX2
43 nevoid hypermelanosis, linear and whorled 9.6 FOXC1 HDAC9 OPTN PITX2
44 myopia 7 9.4 ELP4 FOXC1 IGF2 PAX6 PITX2 WT1
45 skin granular cell tumor 8.3 DCDC5 ELP4 FOXC1 FSHB HDAC9 IGF2

Graphical network of the top 20 diseases related to Iris Disease:



Diseases related to Iris Disease

Symptoms & Phenotypes for Iris Disease

MGI Mouse Phenotypes related to Iris Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.73 FOXC1 IGF2 LOXL1 PAX6 PHEX PITX2
2 muscle MP:0005369 9.63 FOXC1 HDAC9 IGF2 PAX6 PITX2 WT1
3 reproductive system MP:0005389 9.5 FOXC1 FSHB IGF2 LOXL1 PAX6 PITX2
4 respiratory system MP:0005388 9.1 FOXC1 IGF2 LOXL1 PAX6 PITX2 WT1

Drugs & Therapeutics for Iris Disease

Drugs for Iris Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 516)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclopentolate Approved Phase 4 512-15-2 2905
2
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
3
Oxymetazoline Approved Phase 4,Phase 3,Phase 1 1491-59-4 4636
4
Phenylephrine Approved Phase 4,Phase 3,Phase 1 59-42-7 6041
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
6
Tropicamide Approved Phase 4 1508-75-4 5593
7
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 5284616 6436030 46835353
10
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
11
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
12
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2 154598-52-4 64139
13
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
14
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
15
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
16
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3 9004-61-9 53477741 24759
17
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
18
Pilocarpine Approved Phase 4,Phase 3 54-71-7, 92-13-7 5910
19
Colchicine Approved Phase 4 64-86-8 6167 2833
20
Ranibizumab Approved Phase 4,Phase 1,Phase 2 347396-82-1 459903
21
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
22
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
24
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
25
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
26
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
27
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 772 46507594
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
29
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
30
Rifampin Approved Phase 4,Phase 2,Phase 3 13292-46-1 5458213 5381226
31
Lopinavir Approved Phase 4,Phase 2 192725-17-0 92727
32
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
33
Stavudine Approved, Investigational Phase 4,Phase 2,Phase 3 3056-17-5 18283
34
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
35
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 3279 14052
36
Isoniazid Approved Phase 4,Phase 2,Phase 3 54-85-3 3767
37
Pyrazinamide Approved Phase 4,Phase 3,Phase 2 98-96-4 1046
38
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
39
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
40
Nitric Oxide Approved Phase 4 10102-43-9 145068
41
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
42
Certolizumab pegol Approved Phase 4 428863-50-7
43
Citalopram Approved Phase 4 59729-33-8 2771
44
Norepinephrine Approved Phase 4 51-41-2 439260
45
Sertraline Approved Phase 4,Phase 3 79617-96-2 68617
46
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
47
Etravirine Approved Phase 4 269055-15-4 193962
48
Natalizumab Approved, Investigational Phase 4,Phase 1 189261-10-7
49
Pyridoxal Approved, Nutraceutical Phase 4,Phase 2,Phase 1 66-72-8 1050
50
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 65-23-6 1054

Interventional clinical trials:

(show top 50) (show all 535)
id Name Status NCT ID Phase
1 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
2 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4
3 IRIS : Use of Implantable Defibrillator in High-Risk Patients Early After Acute Myocardial Infarction Unknown status NCT00157768 Phase 4
4 A New More Efficient Cycloplegia Scheme Unknown status NCT02177539 Phase 4
5 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4
6 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4
7 Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties Completed NCT01767012 Phase 4
8 Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery Completed NCT02137161 Phase 4
9 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4
10 Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis Completed NCT00108862 Phase 4
11 When to Start Anti-HIV Drugs in Patients With Opportunistic Infections Completed NCT00055120 Phase 4
12 Use of Bevacizumab in Trabeculectomy Surgery Completed NCT01166594 Phase 4
13 Intraoperative Floppy Iris Syndrome Completed NCT00711347 Phase 4
14 The Study to Compare SMART Nitinol Stent and Balloon Angioplasty Completed NCT00309595 Phase 4
15 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4
16 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides Completed NCT00501878 Phase 4
17 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
18 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment Completed NCT01380080 Phase 4
19 Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom Completed NCT01012245 Phase 4
20 Dose, Effects and Characteristics of Pilocarpine Completed NCT00803803 Phase 4
21 Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure Completed NCT00347087 Phase 4
22 Non Steroidal Anti Inflammatory Treatment for Post Operative Pericardial Effusion Completed NCT00247052 Phase 4
23 Cochicine Treatment for Post- Operative Pericardial Effusion Completed NCT01266694 Phase 4
24 Natrecor for Pulmonary Hypertension in Lung Transplants Completed NCT00205426 Phase 4
25 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4
26 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Recruiting NCT03020992 Phase 4
27 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4
28 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Recruiting NCT02949232 Phase 4
29 International Study to Predict Optimised Treatment - in Depression Recruiting NCT00693849 Phase 4
30 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure Active, not recruiting NCT01641367 Phase 4
31 A Study of Survival and Outcome After Stroke Active, not recruiting NCT01193569 Phase 4
32 Standard Versus High Dose Inactivated Influenza Vaccine in RA Enrolling by invitation NCT02936180 Phase 4
33 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Not yet recruiting NCT02769702 Phase 4
34 Appropriate Timing of HAART in Co-infected HIV/TB Patients Terminated NCT01014481 Phase 4
35 Study of TRAVATAN in Subjects With Iris Pigmentation Changes Terminated NCT00047554 Phase 4
36 Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Terminated NCT01211665 Phase 4
37 Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32 Terminated NCT00047606 Phase 4
38 Effect of Methylphenidate on Connectivity Withdrawn NCT01764672 Phase 4
39 Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome Unknown status NCT01455168 Phase 3
40 Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease Unknown status NCT00156611 Phase 2, Phase 3
41 Adalimumab for the Management of Post-operative Crohn's Disease (CD) Unknown status NCT01629628 Phase 3
42 Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma Unknown status NCT00980473 Phase 3
43 Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC Unknown status NCT01249638 Phase 3
44 Randomized Trial of Beta-Carotene and Macular Degeneration Unknown status NCT00000152 Phase 3
45 Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC Unknown status NCT01290783 Phase 3
46 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3
47 The CArdiovasCulAr Diabetes & Ethanol (CASCADE) Trial Unknown status NCT00784433 Phase 3
48 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed NCT00406887 Phase 3
49 A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3
50 Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis Completed NCT01505088 Phase 3

Search NIH Clinical Center for Iris Disease

Cochrane evidence based reviews: iris diseases

Genetic Tests for Iris Disease

Anatomical Context for Iris Disease

MalaCards organs/tissues related to Iris Disease:

39
Eye

Publications for Iris Disease

Variations for Iris Disease

Expression for Iris Disease

Search GEO for disease gene expression data for Iris Disease.

Pathways for Iris Disease

Pathways related to Iris Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 ELP4 FOXC1 PAX6 PITX2

GO Terms for Iris Disease

Cellular components related to Iris Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.23 ELP4 FOXC1 HDAC9 OPTN PAX6 PEX19

Biological processes related to Iris Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.85 FOXC1 FSHB PAX6 PITX2 WT1
2 regulation of transcription from RNA polymerase II promoter GO:0006357 9.78 ELP4 PAX6 PITX2 WT1
3 skeletal system development GO:0001501 9.5 FOXC1 IGF2 PHEX
4 heart development GO:0007507 9.46 FOXC1 HDAC9 PITX2 WT1
5 eye development GO:0001654 9.43 FOXC1 PAX6
6 pituitary gland development GO:0021983 9.4 PAX6 PITX2
7 positive regulation of DNA binding GO:0043388 9.37 FOXC1 PITX2
8 iris morphogenesis GO:0061072 9.26 PAX6 PITX2
9 lacrimal gland development GO:0032808 8.96 FOXC1 PAX6
10 camera-type eye development GO:0043010 8.92 FOXC1 PAX6 PITX2 WT1

Molecular functions related to Iris Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.13 FOXC1 PAX6 PITX2
2 transcription factor binding GO:0008134 8.92 FOXC1 HDAC9 PAX6 PITX2

Sources for Iris Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....